Safety first: pIOL is effective for myopic astigmatism

Article

Implantation of the Artiflex toric iris-fixated phakic IOL is effective, predictable and safe for the correction of myopic astigmatism.

Implantation of the Artiflex toric iris-fixated phakic IOL is effective, predictable and safe for the correction of myopic astigmatism, claims a study in the Journal of Cataract and Refractive Surgery.

Dr Gonzalo Muñoz et al., Refractive Surgery Department, Marqués de Sotelo Ophthalmic Clinic, Barcelona, Spain, conducted a cohort study on 42 eyes of 25 patients age 21 to 39 years.

Refraction, uncorrected (UDVA) and corrected (CDVA) distance visual acuities, complications, pIOL misalignment, and endothelial cell count (ECC) were evaluated 12 months postoperatively. Vector analysis was used to calculate indices of success and misalignment.

Mean spherical equivalent was reduced from −8.85 D ± 2.71 SD to −0.37 ± 0.46 D, with 66.7% of the eyes within ±0.50 D. Mean cylinder power reduced from−2.90 D to −0.39 D. A UDVA of 0.5 or better was achieved in all eyes, along with a CDVA of 0.8 or better.

Mean clinical pIOL misalignment was 2.6 ± 1.8 degrees and one eye required surgical repositioning of the pIOL. Mean ECC reduction was 9.3% ± 1.8%, with iris pigment precipitates observed in 16.7% of eyes. Vector analysis demonstrated excellent mean indices of success for overall, spherical and astigmatic corrections.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.